Vaxart, Inc.’s Groundbreaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced positive safety and immunogenicity data from phase I clinical studies with its oral H1N1 seasonal influenza vaccine candidate. Consequently, the company has initiated a dose-ranging study with its oral H1N1 influenza vaccine. Vaxart is also accelerating development of its oral vaccines for H3N2 influenza and two influenza B-strains, the remaining components of the standard quadrivalent seasonal influenza vaccine.
Help employers find you! Check out all the jobs and post your resume.
SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced positive safety and immunogenicity data from phase I clinical studies with its oral H1N1 seasonal influenza vaccine candidate. Consequently, the company has initiated a dose-ranging study with its oral H1N1 influenza vaccine. Vaxart is also accelerating development of its oral vaccines for H3N2 influenza and two influenza B-strains, the remaining components of the standard quadrivalent seasonal influenza vaccine.
Help employers find you! Check out all the jobs and post your resume.